Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 27.1A Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
29 (8*) |
| Average PDX Generation Time (days +/- SEM) | 82 ± 8 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304; 30049486 |
| Markers | 27.1A Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 27.1A Cx | ZFHX3 | -0.988 | 1.008 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | SMAD2 | -0.962 | 1.027 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | SETDB1 | 0.587 | 3.003 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | RB1 | -28.002 | 7.440e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | PAX6 | -1.028 | 0.981 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | MGA | -0.932 | 1.048 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | MET | 0.585 | 3.000 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | MBD1 | -0.962 | 1.027 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | KMT2C | 0.585 | 3.000 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | FANCA | -0.988 | 1.008 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | EZH2 | 0.585 | 3.000 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | CHD1 | -26.929 | 1.570e-08 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | CDH1 | -0.988 | 1.008 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | BRAF | 0.585 | 3.000 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.1A Cx | AR | -4.026 | 0.061 | GSR | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 27.1A |
|---|---|
| Sample Site | Brain |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, abiraterone |
Patient Information
| Patient Number | 27 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 42 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 27.1A |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.1A Cx | PCDH11X | 187 | 1.0 | Missense variant | '2/7 | . | 22.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | TH | 372 | 0.61 | Start lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | TH | 372 | 0.61 | Start lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | LHFPL3 | 516 | 0.53 | Missense variant | '1/5 | . | 26.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | SON | 395 | 0.51 | Missense variant | '3/12 | . | 25.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | IGF2R | 655 | 0.39 | Missense variant | '16/48 | 3.28E-05 | 24 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | NF1 | 464 | 0.28 | Stop gained | '40/58 | . | 38 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.1A Cx | AR | — | — | GSR | — | — | — | — | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table